Overview
Gliptins have been of interest in the elderly population because they do
not cause postprandial hypoglycemia, attributed to hyposecretion of
GLP-1. Gliptins have a promising role in the control of T2DM, decreasing A1C
without hypoglycemia or weight gain, and with no obvious adverse effect
on cardiovascular outcomes. They appear to be safe in the T2DM elderly
population.
